Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N: Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Canc Treat Rev 2010,36(Suppl 3):S21-S29.
Article
CAS
Google Scholar
Stratton MR, Campbell PJ, Futreal PA: The cancer genome. Nature 2009,458(7239):719–724. 10.1038/nature07943
Article
CAS
PubMed Central
PubMed
Google Scholar
Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S: Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009,6(6):352–366. 10.1038/nrclinonc.2009.62
Article
CAS
PubMed
Google Scholar
Riely GJ, Politi KA, Miller VA, Pao W: Update on epidermal growth factor receptor mutations in Non-small cell lung cancer. Clin Cancer Res 2006,12(24):7232–7241. 10.1158/1078-0432.CCR-06-0658
Article
CAS
PubMed
Google Scholar
Rosell R, Morán T, Carcereny E, Quiroga V, Molina MÁ, Costa C, Benlloch S, Tarón M: Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol 2010,12(2):75–80. 10.1007/S12094-010-0473-0
Article
CAS
PubMed
Google Scholar
Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007,7(3):169–181.
Article
CAS
PubMed
Google Scholar
Stella GM, Luisetti M, Inghilleri S, Cemmi F, Scabini R, Zorzetto M, Pozzi E: Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Respir Med 2012,106(2):173–183. 10.1016/j.rmed.2011.10.015
Article
PubMed
Google Scholar
Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ: Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011,29(24):3316–3321. 10.1200/JCO.2010.33.3757
Article
CAS
PubMed
Google Scholar
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006,355(24):2542–2550. 10.1056/NEJMoa061884
Article
CAS
PubMed
Google Scholar
Cullen MH, Zatloukal P, Sorenson S, Novello S, Fischer JR, Anil AJ, Zereu M, Peterson P, Visseren-Grul C, Iscoe N: Pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC): results from a randomized phase III dose finding trial in patients who progressed following platinum-containing chemotherapy. J Thorac Oncol 2007,2(8):S316-S317.
Article
Google Scholar
Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ: Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 2010,116(16):3903–3909. 10.1002/cncr.25264
Article
CAS
PubMed Central
PubMed
Google Scholar
Scaltriti M, Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006,12(18):5268–5272. 10.1158/1078-0432.CCR-05-1554
Article
CAS
PubMed
Google Scholar
Pao W, Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010,10(11):760–774. 10.1038/nrc2947
Article
CAS
PubMed Central
PubMed
Google Scholar
Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008,3(2):111–116. 10.1097/JTO.0b013e318160c607
Article
PubMed
Google Scholar
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005,23(25):5900–5909. 10.1200/JCO.2005.02.857
Article
CAS
PubMed
Google Scholar
Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009,4(1):22–29. 10.1097/JTO.0b013e3181914111
Article
PubMed
Google Scholar
Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang HY, Chen YT, Hsieh WY, Chen YR, Huang SF: Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol 2010,5(8):1175–1184. 10.1097/JTO.0b013e3181e2f4d6
Article
PubMed
Google Scholar
Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maitre A, Gandara D, Johnson DH, Rigas JR: Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 2011,6(1):139–147. 10.1097/JTO.0b013e3181fd83a4
Article
PubMed Central
PubMed
Google Scholar
Gao J, Chen JQ, Zhang L, Liang ZY: Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system. Zhonghua Bing Li Xue Za Zhi 2012,41(10):652–656.
CAS
PubMed
Google Scholar
Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX: Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006,66(16):8163–8171. 10.1158/0008-5472.CAN-06-0453
Article
CAS
PubMed
Google Scholar
Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J: Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007,67(5):2325–2330. 10.1158/0008-5472.CAN-06-4293
Article
CAS
PubMed
Google Scholar
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010,362(25):2380–2388. 10.1056/NEJMoa0909530
Article
CAS
PubMed
Google Scholar
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009,361(10):958–967. 10.1056/NEJMoa0904554
Article
CAS
PubMed
Google Scholar
Avizienyte E, Ward RA, Garner AP: Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 2008,415(2):197–206. 10.1042/BJ20080728
Article
CAS
PubMed
Google Scholar
Lin L, Bivona TG: Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract 2012, 2012: 817297.
PubMed Central
PubMed
Google Scholar
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008,27(34):4702–4711. 10.1038/onc.2008.109
Article
CAS
PubMed Central
PubMed
Google Scholar
Vadakara J, Borghaei H: Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012, 5: 113–123.
CAS
PubMed Central
PubMed
Google Scholar
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007,67(24):11924–11932. 10.1158/0008-5472.CAN-07-1885
Article
CAS
PubMed
Google Scholar
Ou SH: Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? a review of the clinical evidence. Crit Rev Oncol Hematol 2012,83(3):407–421. 10.1016/j.critrevonc.2011.11.010
Article
PubMed
Google Scholar
Santos E, Martin-Zanca D, Reddy E, Pierotti M, Della Porta G, Barbacid M: Malignant activation of a K-RAS oncogene in lung carcinoma but not in a normal tissue of the same patient. Science 1984, 223: 661–664. 10.1126/science.6695174
Article
CAS
PubMed
Google Scholar
Langer CJ: Roles of EGFR and KRAS mutations in the treatment of patients with Non-small-cell lung cancer. P T 2011,36(5):263–279.
PubMed Central
PubMed
Google Scholar
Riely GJ, Marks J, Pao W: KRAS mutations in Non-small cell lung cancer. Proc Am Thorac Soc 2009,6(2):201–205. 10.1513/pats.200809-107LC
Article
CAS
PubMed
Google Scholar
Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008,14(18):5731–5734. 10.1158/1078-0432.CCR-08-0646
Article
CAS
PubMed Central
PubMed
Google Scholar
Thunnissen FB, Prinsen C, Hol B, Van der Drift M, Vesin A, Brambilla C, Montuenga L, Field JK: Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development. Lung Cancer 2012,75(2):156–160. 10.1016/j.lungcan.2011.07.013
Article
CAS
PubMed
Google Scholar
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005,2(1):e17. 10.1371/journal.pmed.0020017
Article
PubMed Central
PubMed
Google Scholar
Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C: Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res 2009,29(7):2691–2701.
CAS
PubMed
Google Scholar
Benesova L, Minarik M, Jancarikova D, Belsanova B, Pesek M: Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res 2010,30(5):1667–1671.
PubMed
Google Scholar
Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV: Molecular predictors of outcome with gefitinib and docetaxel in previously treated Non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2009,28(5):744–752.
Article
PubMed
Google Scholar
Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA: Role of KRAS and EGFR as biomarkers of response to erlotinib in national cancer institute of canada clinical trials group study BR.21. J Clin Oncol 2008,26(26):4268–4275. 10.1200/JCO.2007.14.8924
Article
CAS
PubMed
Google Scholar
Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced Non-small-cell lung cancer. J Clin Oncol 2011,29(31):4113–4120. 10.1200/JCO.2010.31.8162
Article
CAS
PubMed
Google Scholar
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H: Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 2007,448(7153):561–566. 10.1038/nature05945
Article
CAS
PubMed
Google Scholar
Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H: Identification of novel isoforms of the EML4-ALK transforming gene in Non-small cell lung cancer. Cancer Res 2008,68(13):4971–4976. 10.1158/0008-5472.CAN-07-6158
Article
CAS
PubMed
Google Scholar
Horn L, Pao W: EML4-ALK: honing in on a New target in Non-small-cell lung cancer. J Clin Oncol 2009,27(26):4232–4235. 10.1200/JCO.2009.23.6661
Article
CAS
PubMed
Google Scholar
Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U: Clinical features and outcome of patients with Non-small-cell lung cancer Who harbor EML4-ALK. J Clin Oncol 2009,27(26):4247–4253. 10.1200/JCO.2009.22.6993
Article
CAS
PubMed Central
PubMed
Google Scholar
Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010,9(1):188. 10.1186/1476-4598-9-188
Article
PubMed Central
PubMed
Google Scholar
Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C: ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol 2013. Jan [Epub ahead of print]
Google Scholar
Crystal AS, Shaw AT: New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol 2011,9(3):207–214.
PubMed
Google Scholar
Sasaki T, Rodig SJ, Chirieac LR, Jänne PA: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010,46(10):1773–1780. 10.1016/j.ejca.2010.04.002
Article
CAS
PubMed Central
PubMed
Google Scholar
Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, Matsuo K, Mitsudomi T: Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012,77(2):319–325. 10.1016/j.lungcan.2012.03.013
Article
PubMed
Google Scholar
Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K: Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol 2012,23(11):2931–2936. 10.1093/annonc/mds124
Article
CAS
PubMed
Google Scholar
Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC: EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 2012,7(1):98–104. 10.1097/JTO.0b013e3182370e30
Article
CAS
PubMed
Google Scholar
Wang Z, Zhang X, Bai H, Zhao J, Zhuo M, An T, Duan J, Yang L, Wu M, Wang S: EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology 2012,83(5):248–256. 10.1159/000341381
Article
CAS
PubMed
Google Scholar
Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R: Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol 2010,5(12):2044–2046. 10.1097/JTO.0b013e318200f9ff
Article
PubMed
Google Scholar
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. New Engl J Med 2010,363(18):1734–1739. 10.1056/NEJMoa1007478
Article
CAS
PubMed
Google Scholar
Heuckmann JM, Holzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grutter C: ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011,17(23):7394–7401. 10.1158/1078-0432.CCR-11-1648
Article
CAS
PubMed Central
PubMed
Google Scholar
Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y: CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011,19(5):679–690. 10.1016/j.ccr.2011.04.004
Article
CAS
PubMed
Google Scholar
Feng Y, Thiagarajan PS, Ma PC: MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012,7(2):459–467. 10.1097/JTO.0b013e3182417e44
Article
CAS
PubMed
Google Scholar
Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci 2008,105(2):692–697. 10.1073/pnas.0707270105
Article
CAS
PubMed Central
PubMed
Google Scholar
Organ SL, Tsao MS: An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011,3(1 Suppl):S7-S19. 10.1177/1758834011422556
Article
CAS
PubMed Central
PubMed
Google Scholar
Lawrence RE, Salgia R: MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr 2009,4(1):146–152.
Article
Google Scholar
Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R: The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 2011,3(4):171–184. 10.1177/1758834011408636
Article
CAS
PubMed Central
PubMed
Google Scholar
Ma PC: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in Non-small cell lung cancer. Cancer Res 2005,65(4):1479–1488. 10.1158/0008-5472.CAN-04-2650
Article
CAS
PubMed
Google Scholar
Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K, Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol 2010,5(5):591–596.
PubMed
Google Scholar
Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M: Increased MET gene copy number negatively affects survival of surgically resected Non-small-cell lung cancer patients. J Clin Oncol 2009,27(10):1667–1674. 10.1200/JCO.2008.19.1635
Article
PubMed Central
PubMed
Google Scholar
Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F: Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009,15(18):5714–5723. 10.1158/1078-0432.CCR-09-0070
Article
CAS
PubMed Central
PubMed
Google Scholar
Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011,29(24):3307–3315. 10.1200/JCO.2010.34.0570
Article
CAS
PubMed
Google Scholar
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008,455(7216):1069–1075. 10.1038/nature07423
Article
CAS
PubMed Central
PubMed
Google Scholar
Sharma SV, Settleman J: Oncogenic shock: turning an activated kinase against the tumor cell. Cell Cycle 2006,5(24):2878–2880. 10.4161/cc.5.24.3598
Article
CAS
PubMed
Google Scholar
Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006,9(6):485–495. 10.1016/j.ccr.2006.04.022
Article
CAS
PubMed
Google Scholar
Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II: EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005,65(17):7568–7572.
CAS
PubMed
Google Scholar